2-((1-(3-fluorophenyl)cyclohexyl)amino)-n-hydroxypyrimidine-5-carboxamide

You're asking about **2-((1-(3-fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide**, also known as **PF-06873600**. This compound is a potent and selective **inhibitor of the enzyme histone deacetylase 6 (HDAC6)**.

**Here's why PF-06873600 is important for research:**

* **HDAC6's Role in Disease:** HDAC6 is an enzyme that removes acetyl groups from proteins, a process called deacetylation. This enzyme is linked to various diseases, including cancer, neurodegenerative diseases, and inflammatory disorders. HDAC6 inhibitors like PF-06873600 are being investigated as potential therapeutic agents for these conditions.
* **Mechanism of Action:** PF-06873600 specifically inhibits HDAC6, leading to increased acetylation of target proteins. This can have various beneficial effects, such as:
* **Inhibition of Tumor Growth:** HDAC6 inhibition can alter the acetylation of proteins involved in cell growth and proliferation, potentially slowing or stopping the growth of cancerous cells.
* **Neuroprotection:** HDAC6 inhibitors can protect against cell death in neurodegenerative disorders by affecting protein aggregation and reducing inflammation.
* **Anti-Inflammatory Effects:** HDAC6 inhibition can modulate the immune response by altering the acetylation of proteins involved in inflammation.
* **Preclinical Studies:** Preclinical studies with PF-06873600 have shown promising results in animal models of various diseases. These studies provide evidence for the potential therapeutic use of HDAC6 inhibitors.
* **Clinical Trials:** PF-06873600 has progressed into clinical trials for various diseases, including cancer and neurodegenerative disorders. The results from these trials will determine the safety and efficacy of this drug in humans.

**Overall, PF-06873600 is a promising drug candidate with the potential to treat a variety of diseases by targeting the HDAC6 enzyme. Its mechanism of action and preclinical studies provide a strong basis for continued research and clinical development.**

It's important to note that clinical trials are still ongoing, and the full safety and efficacy of PF-06873600 are yet to be determined.